Comprehensive RITE Reviewer for Internal Medicine
I. GASTROENTEROLOGY
| Topic | Key High-Yield Points | Clinical Pearls |
|---|---|---|
| Upper GI Bleeding - Non-Variceal | • Peptic ulcer disease accounts for 35-50% of cases [1] • Mortality: 11% if admitted for bleeding, 33% if develops in-hospital [1] • Rebleeding definition: Fresh hematemesis/melena + shock (HR >100, SBP <100) OR CVP drop >5mmHg OR Hgb drop >20g/L over 24h [1] |
• Hematemesis + melena = more severe bleeding than melena alone [1] • Haemochezia can indicate massive UGIB [1] • Always confirm rebleeding endoscopically [1] |
| UGIB Management | • Endoscopy timing: Most patients safe for morning elective list; minority need emergency "out of hours" [1] • PPI infusion standard for high-risk lesions • Combined medical-surgical care essential [1] |
• Mortality lower in specialist units due to protocol adherence, not technical advances [1] • 80% have identifiable cause [1] • Coffee ground emesis = altered black blood [1] |
| Anticoagulation in GI Bleeding | • Warfarin: Give 4-factor PCC + low-dose vitamin K for life-threatening bleeding with INR >2.5 [2] • DON'T delay endoscopy until INR normalizes [2] • DOACs: Withhold to facilitate hemostasis; idarucizumab for dabigatran life-threatening bleeding [2] |
• Activated charcoal if DOAC taken within 3 hours [2] • NO vitamin K for DOAC bleeding [2] • NO bridging therapy for DOACs [2] • Avoid high-dose vitamin K (>5mg) in high thromboembolic risk [2] |
| DAPT in GI Bleeding | • NEVER withhold both antiplatelet agents - high stent thrombosis risk [2] • On PPI infusion: Continue aspirin, withhold clopidogrel [2] • Resume P2Y12 inhibitor within 5 days post-hemostasis for drug-eluting stents [2] |
• New generation DES and bare metal stents have similar thrombotic risk [2] • Highest risk first 6 weeks post-PCI [2] |
| Irritable Bowel Syndrome - Diarrhea (IBS-D) | • First-line: Rifaximin for global symptom improvement [3] • TCAs: Effective for abdominal pain and global symptoms • Eluxadoline: For patients without gallbladder (sphincter of Oddi dysfunction risk) • Alosetron: Restricted use, severe constipation/ischemic colitis risk |
• Exclude organic causes before IBS diagnosis [4] • SSRIs less effective than TCAs [3] • Antispasmodics provide short-term relief • Loperamide for diarrhea but not global symptoms [3] |
| Post-Surgical GI Complications | • Anastomotic stricture: Endoscopic dilation first-line; triamcinolone/needle knife for recurrent [4] • Acid reflux: PPIs ± prokinetics up to 6 weeks [4] • Bile reflux: Oral sucralfate suspension [4] • Steatorrhea: Consider PEI, SIBO, severe BAD - test and treat specifically [4] |
• Postprandial pain often from eating too much at once [4] • Don't attribute to IBS until comprehensive workup complete [4] • History of pre-surgery symptoms critical [4] |
| Low Anterior Resection Syndrome (LARS) | • Assess risk with formal scoring tool pre-surgery [4] • Offer supported self-management to all patients [4] • If symptoms persist >3 months: Refer to specialist [4] • Exclude BAD, PEI, SIBO as worsening factors [4] |
• No objective testing required for diagnosis [4] • Pelvic floor exercises improve outcomes [4] • Bulking agents reduce clustering [4] • Transanal irrigation helpful [4] |
II. RHEUMATOLOGY
| Topic | Key High-Yield Points | Clinical Pearls |
|---|---|---|
| Behçet's Disease - Arthritis/Arthralgia | • First-line: Colchicine (increase dose gradually to minimize GI side effects) [5] • Second-line: IM depot or short-course low-dose oral corticosteroids [5] • Refractory: Azathioprine or anti-TNF therapy [5] • Consider: Apremilast, methotrexate, MMF, secukinumab (≥6 years) [5] |
• NSAIDs alternative to steroids if no contraindication [6] • Intra-articular steroids for mono/oligoarticular synovitis [5] • Caution with MTX: Can worsen extensive mouth ulceration [6] • Refer to PT/OT/podiatry as needed [5] |
| Behçet's Disease - Gastrointestinal | • Acute flares: Oral/IV corticosteroids first-line [5] • Mild-moderate: 5-ASA for aphthous/superficial ulcers [5] • Moderate-severe OR large/deep ulcers: Azathioprine or 6-MP to prevent perforation/bleeding/obstruction [5] • Severe OR large/deep ulcers: Consider anti-TNF early as first-line [5] |
• Taper steroids 7-10 days after clinical remission [5] • Flares common during/after steroid taper [5] • Start tapering steroids when starting 5-ASA/AZA/6-MP [6] • Anti-TNF dose escalation/interval reduction for resistant cases [5] |
| Behçet's GI - Surgery & Post-Op | • Emergency surgery: Life-saving for uncontrolled bleeding, perforation, obstruction [5] • Post-resection prophylaxis: AZA or 6-MP first-line [5] • Consecutive resections: Systemic steroids + anti-TNF + AZA to prevent pathergy-like relapse [5] |
• Concomitant immunomodulators (AZA/6-MP) with anti-TNF achieve early sustained response [6] • Consider IBD therapies (JAK inhibitors, ustekinumab, vedolizumab) if refractory [5] • Continue treatment ≥2 years after endoscopic remission [5] |
| JAK-STAT GOF Inborn Errors | • JAK inhibitors: Promising targeted treatment for JAK-STAT gain-of-function IEI [7] • Requires comprehensive pretreatment workup and monitoring [7] • Can serve as bridge to HSCT [7] |
• Implementation barriers: Cost, limited access to monitoring [7] • Standardized protocols needed globally [7] • Adapt to local healthcare infrastructure [7] |
III. NEUROLOGY
| Topic | Key High-Yield Points | Clinical Pearls |
|---|---|---|
| Neurologic Manifestations in Systemic Disease | • Behçet's can cause sight-threatening eye disease requiring oral/IV corticosteroids first-line [6] | • Multidisciplinary approach essential for complex cases • Early recognition prevents irreversible damage |
| Post-Transplant Neurologic Complications | • After HSCT: GI toxicity predicts post-transplant complications [4] • Multidisciplinary care includes neurology input for symptom control [4] |
• Cytomegalovirus can cause neurologic manifestations post-HSCT [4] • Early specialist involvement improves outcomes |
IV. ALLERGOLOGY/IMMUNOLOGY
| Topic | Key High-Yield Points | Clinical Pearls |
|---|---|---|
| Hematopoietic Stem Cell Transplant - GI/Immune | • GI toxicity predicts post-transplant complications [4] • Multidisciplinary approach: Hematology, dietitian, gastroenterology, symptom control [4] • Diagnostic workup: Endoscopy with small bowel aspirate/biopsies for diarrhea [4] • Differentiate: SIBO, fungal overgrowth, C. diff, CMV, GvHD [4] |
• Upper endoscopy + sigmoidoscopy safer than colonoscopy with similar diagnostic yield [4] • Wireless capsule NOT recommended for GvHD diagnosis [4] • Don't delay treatment for typical GvHD while awaiting biopsy [4] |
| Neuroendocrine Neoplasms (NENs) | • Most GI symptoms NOT from hormone excess [4] • Gastroenterologists should be in NEN MDT [4] • Surgery and systemic treatments (especially somatostatin analogues) frequently cause GI symptoms [4] |
• Comprehensive symptom assessment needed • Don't assume all symptoms are hormone-related • Multidisciplinary management essential |
| Drug Hypersensitivity in Rheumatologic Disease | • Thalidomide for refractory GI Behçet's: Last resort only [6] • Mandatory: Neurophysiology monitoring + contraception counseling for both sexes [6] • Can combine with anti-TNF for better outcomes [6] |
• High teratogenicity risk requires strict protocols • Peripheral neuropathy monitoring essential • Consider all IBD treatment options before thalidomide [5] |
V. CROSS-CUTTING CONCEPTS FOR RITE SUCCESS
| Category | Essential Knowledge |
|---|---|
| Evidence Grading | • Grade A: RCTs/systematic reviews • Grade B: Non-randomized cohorts, case series • Grade C: Expert opinion, physiology-based [1] |
| Anticoagulation Bridging | • High risk: CHADS-VASc >5, metallic mitral valve, prosthetic valve + AF, <3 months post-VTE, severe thrombophilia [2] • Low risk: NO bridging recommended [2] |
| Common RITE Pitfalls | • Crystalline arthritis and osteoarthritis: Often tested despite perceived "ease" [8] • Rheumatology knowledge gaps common across all PGY levels [9] • GI physical exam frequently inadequate (58.6% "needs improvement") [10] |
| Test-Taking Strategy | • ITE scores improve predictably with each training year [11] • IMGs consistently outperform US grads since 1995 [11] • Timing and available time affect performance [11] |